Literature DB >> 9309117

Hypermethylation in the retinoblastoma gene is associated with unilateral, sporadic retinoblastoma.

N Ohtani-Fujita1, T P Dryja, J M Rapaport, T Fujita, S Matsumura, K Ozasa, Y Watanabe, K Hayashi, K Maeda, S Kinoshita, T Matsumura, Y Ohnishi, Y Hotta, R Takahashi, M V Kato, K Ishizaki, M S Sasaki, B Horsthemke, K Minoda, T Sakai.   

Abstract

We previously reported 9 unilateral, sporadic retinoblastomas with hypermethylation in the 5' region of the RB gene, and we found that CpG methylation in the RB promoter inhibits the binding of the retinoblastoma binding factor 1 (RBF-1) and the activating transcription factor (ATF)-like factors, thereby resulting in a considerable reduction in RB promoter activity. In this study, we screened for hypermethylation in 121 additional cases of retinoblastoma, and found 5 tumors with hypermethylation, including 4 unilateral, sporadic tumors, and one hereditary tumor. The hereditary tumor had a germline deletion of one allele, and the hypermethylation was an acquired, epigenetic change in the other allele. Another tumor had hypermethylation restricted to approximately 800 base pairs in the RB promoter region including the essential RBF-1 and ATF sites. The frequency of hypermethylation in unilateral, sporadic tumors was 9.3% combining our previous and present examinations (13 among 140), whereas the frequency was 1.0% in bilateral hereditary tumors (one among 101). The statistical analyses using the chi-square test indicated significant correlation between hypermethylation and unilateral, sporadic tumors (p < 0.05). These results suggest that hypermethylation in the RB gene is always an acquired, epigenetic change and causes about 9% of unilateral, sporadic tumors.

Entities:  

Mesh:

Year:  1997        PMID: 9309117     DOI: 10.1016/s0165-4608(96)00395-0

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  38 in total

Review 1.  Epigenetic gene silencing in cancer.

Authors:  B Tycko
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

2.  Epigenetics and assisted reproductive technology: a call for investigation.

Authors:  Emily L Niemitz; Andrew P Feinberg
Journal:  Am J Hum Genet       Date:  2004-02-27       Impact factor: 11.025

3.  Risk of retinoblastoma is associated with a maternal polymorphism in dihydrofolatereductase (DHFR) and prenatal folic acid intake.

Authors:  Manuela A Orjuela; Lourdes Cabrera-Muñoz; Ligi Paul; Marco A Ramirez-Ortiz; Xinhua Liu; Jia Chen; Fabiola Mejia-Rodriguez; Aurora Medina-Sanson; Silvia Diaz-Carreño; Ida H Suen; Jacob Selhub; M Veronica Ponce-Castañeda
Journal:  Cancer       Date:  2012-05-30       Impact factor: 6.860

Review 4.  Molecular screening of cancer: the future is here.

Authors:  Sudhir Srivastava
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

5.  The retinoblastoma gene product interacts with maintenance human DNA (cytosine-5) methyltransferase and modulates its activity.

Authors:  Sriharsa Pradhan; Gun-Do Kim
Journal:  EMBO J       Date:  2002-02-15       Impact factor: 11.598

6.  TET repression and increased DNMT activity synergistically induce aberrant DNA methylation.

Authors:  Hideyuki Takeshima; Tohru Niwa; Satoshi Yamashita; Takeji Takamura-Enya; Naoko Iida; Mika Wakabayashi; Sohachi Nanjo; Masanobu Abe; Toshiro Sugiyama; Young-Joon Kim; Toshikazu Ushijima
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

7.  Increased incidence and disparity of diagnosis of retinoblastoma patients in Guatemala.

Authors:  Michael Dean; Giovana Bendfeldt; Hong Lou; Veronica Giron; Claudia Garrido; Patricia Valverde; Margarita Barnoya; Mauricio Castellanos; Silvia Jiménez-Morales; Sandra Luna-Fineman
Journal:  Cancer Lett       Date:  2014-05-06       Impact factor: 8.679

8.  Low-penetrant RB allele in small-cell cancer shows geldanamycin instability and discordant expression with mutant ras.

Authors:  Yoonsoo Park; Akihito Kubo; Takefumi Komiya; Amy Coxon; Kristin Beebe; Len Neckers; Paul S Meltzer; Frederic J Kaye
Journal:  Cell Cycle       Date:  2008-05-30       Impact factor: 4.534

9.  Biomarkers in bladder cancer: present status and perspectives.

Authors:  Wun-Jae Kim; Soongang Park; Yong-June Kim
Journal:  Biomark Insights       Date:  2007-03-27

10.  Epimutations, inheritance and causes of aberrant DNA methylation in cancer.

Authors:  David Mossman; Rodney J Scott
Journal:  Hered Cancer Clin Pract       Date:  2006-05-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.